Larimar Therapeutics, Inc.

NasdaqGM:LRMR Stok Raporu

Piyasa değeri: US$323.6m

Larimar Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Larimar Therapeutics CEO'su Carole Ben-Maimon, May2020 tarihinde atandı, in görev süresi 6.08 yıldır. in toplam yıllık tazminatı $ 3.53M olup, şirket hissesi ve opsiyonları dahil olmak üzere 18.4% maaş ve 81.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.11% ine doğrudan sahiptir ve bu hisseler $ 358.41K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.9 yıl ve 5.9 yıldır.

Anahtar bilgiler

Carole Ben-Maimon

İcra Kurulu Başkanı

US$3.5m

Toplam tazminat

CEO maaş yüzdesi18.43%
CEO görev süresi6.1yrs
CEO sahipliği0.1%
Yönetim ortalama görev süresi5.9yrs
Yönetim Kurulu ortalama görev süresi5.9yrs

Son yönetim güncellemeleri

Recent updates

Analiz Makalesi • Jan 24

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jan 16

Larimar Therapeutics: The Market Is Mispricing A Potential Standard Of Care

Summary Larimar Therapeutics is deeply undervalued, trading at ~$3.40 despite a de-risked safety profile and a clear regulatory path for its lead asset. Nomlabofusp directly addresses Friedreich’s Ataxia’s root cause, with a mechanism that delivers missing frataxin, potentially supplanting current standard-of-care. Anaphylaxis concerns have been mitigated by new dosing protocols and FDA-approved trial modifications, positioning LRMR for a potential re-rating. With $175.4m cash runway into Q4-26 and multiple near-term catalysts, LRMR offers asymmetric risk-reward, targeting a 3-5x return if milestones are met. Read the full article on Seeking Alpha
Analiz Makalesi • May 28

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jan 03

Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better

Summary Larimar Therapeutics, Inc. reported initial positive data from phase 2 long-term OLE study using nomlabofusp for treatment of patients with Friedreich's Ataxia; Increase of tissue FXN protein levels from 15% to 30%. The global Friedreich's Ataxia market size is projected to reach $2.06 billion by 2030. Additional data using higher 50 mg dose of nomlabofusp to treat patients with Friedreich's Ataxia expected in mid-2025. Accelerated Approval BLA filing of nomlabofusp for patients with Friedreich's Ataxia might be possible 2nd half of 2025 on basis of a surrogate biomarker endpoint of FXN protein levels. Read the full article on Seeking Alpha
Analiz Makalesi • Dec 18

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Oct 07

Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential

Summary Larimar Therapeutics' CTI-1601, a potential first-in-class treatment for Friedreich's ataxia, shows promise in modifying disease progression and restoring mitochondrial function. The company has a solid cash runway, sufficient liquidity, and trades at reasonable valuations compared to its upside potential. LRMR's favorable Phase 1/2 trial results bolster CTI-1601's approval odds, with a potential Biologics License Application submission by 2H2025. Additionally, CTI-1601 has multiple FDA and EU designations, potentially expediting its development and approval process. Despite competition risks, LRMR's unique approach and sufficient resources make it a speculative "Buy" for investors aware of inherent biotech risks. Read the full article on Seeking Alpha
Analiz Makalesi • Aug 09

Larimar Therapeutics (NASDAQ:LRMR) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Jul 15

Larimar Therapeutics: More Data Still Needed

Summary Larimar Therapeutics' stock has surged 50% after its FA therapy was selected for FDA's START program, aiming for a BLA filing in 2H25. Its lead candidate Nomlabofusp is a protein replacement therapy for Friedreich's ataxia, competing with Biogen's Skyclarys and other potential treatments. Larimar has enough cash to fund operations until 2026, with analyst optimism and a timeline to potentially beat competitors to the market. Can the recent rally in the shares continue? A full investment analysis follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • May 31

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

Summary Partial clinical hold from FDA, for use of nomlabofusp for the treatment of patients with Friedreich's Ataxia completely lifted; higher dosing of 50 mg of treatment now possible. It is expected that the global Friedreich's Ataxia market could reach $2.06 billion by 2030. Interim data from the ongoing phase 2 open-label study, using nomlabofusp for the treatment of patients with Friedreich's Ataxia, expected Q4 of 2024. Nomlabofusp for the treatment of patients with Friedreich's Ataxia selected as part of the FDA pilot program known as START, which is intended to accelerate the development of drugs that target rare unmet medical needs. Read the full article on Seeking Alpha
Analiz Makalesi • Nov 13

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • May 19

Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analiz Makalesi • Feb 02

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 20

Laramar Therapeutics issued patent for lead pipeline candidate

Larimar Therapeutics (NASDAQ:LRMR) has been granted a composition of matter patent covering CTI-1601, its lead pipeline candidate for Friedreich’s ataxia. The patent provides coverage through at least July 2040. CTI-1601, currently in phase 1, has Fast Track and Orphan Drug designation from the US FDA. The company plans to begin a phase 2 trial for CTI-1601 by the end of the year. Seeking Alpha's Quant Rating views Larimar (LRMR) as a strong buy with high marks for momentum and revisions.
Seeking Alpha • Sep 14

Larimar Therapeutics prices ~$70M stock offering

Larimar Therapeutics (NASDAQ:LRMR) has priced of an underwritten offering of 22,225,000 shares of common stock at $3.15 per share. Underwriters have been granted a 30-day overallotment option to purchase up to 3,333,750 additional shares of common stock at the offering price. Gross proceeds to Larimar (LRMR) are expected to be ~$70M. The offering is expected to close around Sep 16, 2022. The biotech company also received FDA clearance to initiate the 25mg cohort of a Phase 2 Dose exploration trial of its lead compound, CTI-1601, in Friedreich's ataxia patients. It plans to begin the Phase 2 trial in Q4 2022, with top-line data expected in 2H 2023. CTI-1601 is a recombinant fusion protein intended to deliver human frataxin to the mitochondria of patients with Friedreich's ataxia who are unable to produce enough of this essential protein. LRMR shares have gained 2% pre-market on the news
Analiz Makalesi • Sep 02

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Aug 11

Larimar Therapeutics GAAP EPS of -$0.47

Larimar Therapeutics press release (NASDAQ:LRMR): Q2 GAAP EPS of -$0.47. Cash and marketable debt securities at June 30, 2022 of $54.9 million provides projected cash runway through the third quarter of 2023
Analiz Makalesi • Mar 21

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Dec 18

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analiz Makalesi • Feb 08

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO Tazminat Analizi

Carole Ben-Maimon'un ücretlendirmesi Larimar Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Mar 31 2026n/an/a

-US$166m

Dec 31 2025US$4mUS$650k

-US$166m

Sep 30 2025n/an/a

-US$132m

Jun 30 2025n/an/a

-US$100m

Mar 31 2025n/an/a

-US$95m

Dec 31 2024US$3mUS$600k

-US$81m

Sep 30 2024n/an/a

-US$65m

Jun 30 2024n/an/a

-US$58m

Mar 31 2024n/an/a

-US$45m

Dec 31 2023US$3mUS$560k

-US$37m

Sep 30 2023n/an/a

-US$33m

Jun 30 2023n/an/a

-US$33m

Mar 31 2023n/an/a

-US$33m

Dec 31 2022US$2mUS$528k

-US$35m

Sep 30 2022n/an/a

-US$35m

Jun 30 2022n/an/a

-US$44m

Mar 31 2022n/an/a

-US$47m

Dec 31 2021US$2mUS$510k

-US$51m

Sep 30 2021n/an/a

-US$56m

Jun 30 2021n/an/a

-US$49m

Mar 31 2021n/an/a

-US$48m

Dec 31 2020US$5mUS$268k

-US$42m

Tazminat ve Piyasa: Carole 'nin toplam tazminatı ($USD 3.53M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.63M ).

Tazminat ve Kazançlar: Carole şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Carole Ben-Maimon (67 yo)

6.1yrs
Görev süresi
US$3,526,423
Tazminat

Dr. Carole S. Ben-Maimon, M.D., is President, Chief Executive Officer and Director at Larimar Therapeutics, Inc. since May 28, 2020. She was Chief Executive Officer, President and Director at Chondrial The...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Carole Ben-Maimon
CEO, President & Director6.1yrsUS$3.53m0.11%
$ 358.4k
Michael Celano
Secretary & CFO6.1yrsUS$1.70m0.11%
$ 365.6k
Gopi Shankar
Chief Development Officer3.3yrsUS$1.29m0.021%
$ 68.4k
John Berman
Vice President of Finance & Administration2.8yrsVeri yokVeri yok
Jennifer Johansson
Vice President of Legal & Compliance9.5yrsVeri yokVeri yok
Russell Clayton
Chief Medical Officer2.9yrsVeri yok0.068%
$ 221.5k
Francis Conway
VP & Controller5.9yrsVeri yokVeri yok
5.9yrs
Ortalama Görev Süresi
66yo
Ortalama Yaş

Deneyimli Yönetim: LRMR 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.9 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Carole Ben-Maimon
CEO, President & Director6.1yrsUS$3.53m0.11%
$ 358.4k
Jonathan Leff
Independent Director6.1yrsUS$74.90k0%
$ 0
Jeffrey Sherman
Independent Director2.7yrsUS$66.15k0.0048%
$ 15.5k
Frank Thomas
Independent Director12yrsUS$82.40k0.0067%
$ 21.7k
Thomas Hamilton
Independent Director6.1yrsUS$73.65k0.79%
$ 2.6m
Joseph Truitt
Independent Chairman of the Board6.1yrsUS$109.90k0.0026%
$ 8.5k
Giovanni Manfredi
Member of Scientific Advisory Board5.7yrsVeri yokVeri yok
Mark Payne
Member of Scientific Advisory Board5.7yrsVeri yokVeri yok
Marni Falk
Member of Scientific Advisory Board5.7yrsVeri yokVeri yok
Jill Ostrem
Member of Scientific Advisory Board3.8yrsVeri yokVeri yok
5.9yrs
Ortalama Görev Süresi
59.5yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: LRMR 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.9 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/06/09 13:35
Gün Sonu Hisse Fiyatı2026/06/09 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Larimar Therapeutics, Inc. 16 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Christopher ChenBaird
null nullBaird
Joel BeattyBaird